| | | ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch
ImmunityBio, Inc. ( NASDAQ: IBRX), a leading immunotherapy company, today announced details about its Investor Day program to be held on Tuesday, April 15, 2025, at 10:00 am PDT. The program will include an in-depth update on the company’s business operations, U.S. and global regulatory advances of its clinical-stage products, with fireside chats hosted by Dr. Patrick Soon-Shiong and key opinion leaders involved in the company’s research programs.
The discussions will include clinical and regulatory updates on the company’s bladder cancer program, regenerative medicine advanced therapy (RMAT) designations, including results on non-small cell lung cancer (NSCLC) and metastatic pancreatic cancer trials, as well as lymphopenia rescue data related to these trials (Cancer BioShield).
In addition, updates will be provided on the natural killer (NK) cell therapy program, the Lynch syndrome accrual and fireside chats on virally induced cancers, including discussions on Long-COVID.
The key opinion leaders participating in the fireside chats with ImmunityBio leadership include:
- Dr. Christopher Pieczonka – Chief Executive Officer, Associated Medical Professionals of New York & Corporate Director of Clinical Research of US Urology Partners
- Dr. Steven Finkelstein – National Director of Radiation Oncology, US Urology Partners. Director of the Center of Advanced Radiation Excellence (CARE) and Director Radiation Oncology Research
- Dr. Mark Lanasa – Senior Vice President, Chief Medical Officer, Solid Tumors, BeiGene
- Dr. Jennifer Buell – President & Chief Executive Officer, MiNK Therapeutics
- Dr. Krishnansu Tewari – Gynecologic Oncology, Obstetrics & Gynecology at UC Irvine Health
- Dr. David Kerr - Professor of Cancer Medicine Genetics and Genomics, University of Oxford
- Dr. Timothy Heinrich – Professor, School of Medicine UC San Francisco
- Dr. Carlos Cardo-Cardon – Chairman for the Mount Sinai Health System Dept. of Pathology
Key timelines for catalysts of product candidates will be presented, along with a discussion of ongoing clinical trials.
The program will feature a presentation by ImmunityBio Founder, Executive Chairman and Global Chief Scientific and Medical Officer, Dr. Patrick Soon-Shiong, outlining the fundamental science underpinning the company’s technology platforms. This technology harnesses the immune system to deliver long-term disease protection and prevention.
This limited space event will be held in person in El Segundo, California. Individuals wishing to attend in person must RSVP in advance via email ( investorday2025@immunitybio.com). The event will also be live-streamed.
The live stream can be found at:
cts.businesswire.com
Participant Listening (Listen Only)
1-844-539-3703 or 1-412-652-1273
newsfile.refinitiv.com |
|
